The Edinburgh Pharmacology Symposium 2016 took place on Thursday 5th May. PROGRAMME Opening Address: Professor JS Kelly 9.00-10.45am Session 1 - Small molecule modulation of gene expression Chair: Professor Mark Evans Plenary Lecture - Selective modulation of gene expression using bromodomain inhibitors Dr Rab Prinjha, VP Head of Epigenetics DPU, Immunoinflammation TA Unit, GSK Medicines Research Centre, Stevenage, UK. Therapeutic potential of micro-RNA Professor Andy Baker, BHF Professor of Translational, Cardiovascular Sciences, Gustav Born Chair of Vascular Biology, Centre for Cardiovascular Science, University of Edinburgh. Why target DNA modification reprogramming in cancer? Professor Richard Meehan, Chromosomes and Gene Expression Programme Leader, Institute of Genetics and Molecular Medicine, University of Edinburgh. COFFEE 11.15-12.45pm Session 2 - Subunit- and subtype-selective modulation of enzymes and receptors: delivering cell and system specificity Chair: Dr Christos Gkogas Subunit-selective modulation of AMPK: from cell to system Professor Mark Evans, Chair of Cellular Pharmacology, Centre for Integrative Physiology, University of Edinburgh Pharmacological modulation of 5alpha-reductase Dr Dawn Livingstone, Lecturer, Centre for Integrative Physiology, University of Edinburgh. Enhanced analgesia from combined targeting of a receptor:channel signalling complex Professor Sue Fleetwood-Walker, Chair of Sensory Neuroscience, Centre for integrative Physiology, University of Edinburgh. LUNCH 2.00-3.30pm Session 3 Overcoming barriers to innovation in academic drug discovery Chair: Professor Michael Eddleston Discovery of KMO inhibitors for potential treatment of organ failure Dr Scott Webster, Senior Lecturer and Director of Drug Discovery Core, Centre for Cardiovascular Science, University of Edinburgh Targeting the Glycolytic Pathway for Trypanocidal Drugs Prof Malcolm Walkinshaw, Chair of Structural Biochemistry and Director, Centre for Translational and Chemical Biology, University of Edinburgh. Scaffold hopping approaches to novel Autotaxin inhibitors Dr Craig Jamieson, Senior Lecturer, Pure and Applied Chemistry, University of Strathclyde, Glasgow, UK. COFFEE 4.00-5.30pm Session 4 Pro-drugs and combinatorial therapies: tipping the balance towards a cancer cure Chair: Dawn Livingstone Novel Inhibitors of Tryptophan Metabolism as Cancer Immunotherapies Dr Philip Cowley, Head of Chemistry, IOMET Pharma, Edinburgh, UK Understanding resistance to cancer therapies Professor Val Brunton, Chair of Cancer Therapeutics, Centre for Cancer Therapeutics, University of Edinburgh The role of tumour microenvironment in prostate cancer resistance to androgen deprivation therapy Dr Binzhi Qian, Chancellor’s Fellow & CRUK Career Development Fellow Edinburgh Cancer Research UK Centre & MRC University of Edinburgh Centre for Reproductive Health. 5.30-7pm Wine Reception Further information Please contact: Prof A. Mark Evans Prof Michael Eddleston Dr Anne Leaver (BPS Ambassador) Publication date 25 Jul, 2017
